What changed
2026-07-29 21:34 UTC → 2026-07-31 12:52 UTC ·
added
removed
In mid‑July, Pulmonx Corp disclosed After a sharp 49 % drop in short interest, with interest in mid‑July, Pulmonx Corp saw hedge funds such as Bank of America, ADAR1 Capital Management and Renaissance Technologies increasing increase their stakes. The company noted a modest stakes while its share price decline and announced that its hovered near $1.25. The company’s Q2 2026 earnings would be presented on July 29. When the earnings were released at the end of July, Pulmonx reported worldwide on July 29, confirming earlier guidance. Worldwide revenue of was $22.8 million, down a 5 % year‑over‑year, year‑over‑year decline, with U.S. sales slipping falling 4 % to $14.2 million and international sales falling revenue decreasing 6 % (excluding to $8.6 million, primarily because of no sales in China. Excluding China, overseas revenue rose 12 %). Despite lower sales, the %. The quarter achieved delivered a record gross margin of 78 % and reduced trimmed the net and adjusted EBITDA losses loss by roughly one‑third, leading to one‑third (34 % versus the prior year), producing earnings per share of –$0.24, beating which beat consensus estimates. Shares remained flat around $1.25, $1.25 and the CEO expressed reiterated confidence in returning to revenue growth. The earnings release was noted alongside other market updates, such as Barclays raising its price target for Blue Owl Capital.